Atrial Fibrillation | UMCG | Ongoing community-based cohort research
43
portfolio_page-template-default,single,single-portfolio_page,postid-43,ajax_fade,page_not_loaded,,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-4.12,vc_responsive

Ongoing community-based cohort research

Prevention of Renal and Vascular Endstage Disease (PREVEND) study

The community-based PREVEND cohort (www.prevend.org) is an observational follow-up study (started in 1997), including 8592 individuals from the city of Groningen. The baseline screening program consisted of 2 outpatient visits to assess demographic factors, anthropometric measurements, cardiovasclar and metabolic risk factors, and health behavior and to collect blood samples and two 24-h urine samples on two consecutive days.

Participants were seen at 3-year intervals in the PREVEND outpatient clinic. Over 10 years of follow-up and data on cardiovascular morbidity and mortality, including atrial fibrillation is available. Within PREVEND, Rienstra focuses on cardiovascular risk factors, genetics, and atrial fibrillation.

 

Lifelines cohort study

The Northern Netherlands community-based Lifelines cohort (www.lifelines.nl) is an observational follow-up study (started in 2007), including >165,000 individuals covering three generations. Each participant has been extensively phenotyped at baseline, and will be followed for at least 30 years at 5-year intervals. Follow-up on morbidity and mortality are based on general practitioners, hospital and pharmacy records. Within Lifelines, Rienstra focuses on cardiovascular risk factors, genetics, ECG, and atrial fibrillation.